Daiichi Sankyo Company Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $27.28
- Today's High:
- $28.91
- Open Price:
- $27.44
- 52W Low:
- $22.0041
- 52W High:
- $36.73
- Prev. Close:
- $28.9
- Volume:
- 10900
Company Statistics
- Market Cap.:
- $65.84 billion
- Book Value:
- 754.092
- Revenue TTM:
- $1,278.48 billion
- Operating Margin TTM:
- 9.43%
- Gross Profit TTM:
- $691.56 billion
- Profit Margin:
- 8.54%
- Return on Assets TTM:
- 3.19%
- Return on Equity TTM:
- 7.81%
Company Profile
Daiichi Sankyo Company Limited had its IPO on under the ticker symbol DSKYF.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Daiichi Sankyo Company Limited has a staff strength of 0 employees.
Stock update
Shares of Daiichi Sankyo Company Limited opened at $27.44 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $27.28 - $28.91, and closed at $28.74.
This is a -0.55% slip from the previous day's closing price.
A total volume of 10,900 shares were traded at the close of the day’s session.
In the last one week, shares of Daiichi Sankyo Company Limited have increased by 0%.
Daiichi Sankyo Company Limited's Key Ratios
Daiichi Sankyo Company Limited has a market cap of $65.84 billion, indicating a price to book ratio of 5.8531 and a price to sales ratio of 0.0568.
In the last 12-months Daiichi Sankyo Company Limited’s revenue was $1,278.48 billion with a gross profit of $691.56 billion and an EBITDA of $188.37 billion. The EBITDA ratio measures Daiichi Sankyo Company Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Daiichi Sankyo Company Limited’s operating margin was 9.43% while its return on assets stood at 3.19% with a return of equity of 7.81%.
In Q4, Daiichi Sankyo Company Limited’s quarterly earnings growth was a negative -10.8% while revenue growth was a positive 41.2%.
Daiichi Sankyo Company Limited’s PE and PEG Ratio
- Forward PE
- 62.8931
- Trailing PE
- 156.1364
- PEG
- 31575.3
Its diluted EPS in the last 12-months stands at $0.22 per share while it has a forward price to earnings multiple of 62.8931 and a PEG multiple of 31575.3. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Daiichi Sankyo Company Limited’s profitability.
Daiichi Sankyo Company Limited stock is trading at a EV to sales ratio of 0.0515 and a EV to EBITDA ratio of 0.3815. Its price to sales ratio in the trailing 12-months stood at 0.0568.
Daiichi Sankyo Company Limited stock pays annual dividends of $30 per share, indicating a yield of 0.74% and a payout ratio of 0.38%.
Balance sheet and cash flow metrics
- Total Assets
- $2,398.03 billion
- Total Liabilities
- $457.07 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $17.59 billion
- Dividend Payout Ratio
- 0.38%
Daiichi Sankyo Company Limited ended 2024 with $2,398.03 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2,398.03 billion while shareholder equity stood at $1,414.32 billion.
Daiichi Sankyo Company Limited ended 2024 with $0 in deferred long-term liabilities, $457.07 billion in other current liabilities, 50000000000.00 in common stock, $1,204.63 billion in retained earnings and $94.97 billion in goodwill. Its cash balance stood at $395.18 billion and cash and short-term investments were $795.19 billion. The company’s total short-term debt was $41,396,000,000 while long-term debt stood at $101.79 billion.
Daiichi Sankyo Company Limited’s total current assets stands at $1,437.61 billion while long-term investments were $0 and short-term investments were $400.01 billion. Its net receivables were $355.36 billion compared to accounts payable of $358.38 billion and inventory worth $266.69 billion.
In 2024, Daiichi Sankyo Company Limited's operating cash flow was $0 while its capital expenditure stood at $17.59 billion.
Comparatively, Daiichi Sankyo Company Limited paid $0.00 in dividends in 2024.
Other key metrics
- Current Trading Price
- $28.74
- 52-Week High
- $36.73
- 52-Week Low
- $22.0041
- Analyst Target Price
- $
Daiichi Sankyo Company Limited stock is currently trading at $28.74 per share. It touched a 52-week high of $36.73 and a 52-week low of $36.73. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $29.01 and 200-day moving average was $32.14 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 144.5% of the company’s stock are held by insiders while 5658% are held by institutions.
Frequently Asked Questions About Daiichi Sankyo Company Limited
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; and ferric carboxymaltose injection for treating anemia. It also provides edoxaban, an oral, once-daily, direct factor Xa inhibitor; esaxerenone and olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastases from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.